May 28, 2024 8:00am EDT Tonix Pharmaceuticals Announces Presentation at the 2024 BIO International Convention
May 22, 2024 8:00am EDT Tonix Pharmaceuticals to Deliver an Oral Presentation and Present Two Posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 21, 2024 8:00am EDT Tonix Pharmaceuticals Announces Key Findings from Initial Phase of EVERSANA Market Opportunity Analysis for Tonmya™ for the Management of Fibromyalgia
May 15, 2024 8:00am EDT Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
May 13, 2024 4:30pm EDT Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights
Apr 1, 2024 4:15pm EDT Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Mar 28, 2024 9:32am EDT Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
Mar 25, 2024 8:00am EDT Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
Mar 21, 2024 8:00am EDT Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
